Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Sun Pharma has made its play just three months after Checkpoint won FDA approval for PD-L1 inhibitor Unloxcyt (cosibelimab) ...

Sun Pharma’s acquisition of Checkpoint Therapeutics includes Unloxcyt, an FDA-approved anti-PD-L1 therapy for metastatic and ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

India's pharma giant Sun Pharma to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology ...

(Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire ...

Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This ...

Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Checkpoint Therapeutics, Inc., a ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun ...

Sun Pharmaceutical Industries on Monday said it will acquire immunotherapy and targeted oncology firm, Inc for up to USD 355 ...

Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma ...